The effect of N-acetyl cysteine injection on renal function after coronary artery bypass graft surgery : A randomized clinical trial

Objective: This study aimed to compare the effects of N-acetyl cysteine on renal function after coronary artery bypass graft surgery. Method: In this randomized clinical trial conducted in Golestan Hospital, Ahvaz, Iran, 60 candidates for coronary artery bypass graft surgery were selected and divided into two N-acetyl cysteine and control groups (30 people each). Intervention: Patients received 3 (2 intraoperative and 1 postoperative) doses of IV N-acetyl cysteine (100 mg/kg) (n=30) or placebo (n=30) over 24 hour. Prescription times were as follows: after induction of anesthesia, in the Next 4 hours, and in the 16 hours after on. Primary outcomes were serum levels of BUN and Cr, at baseline,4 and 48 hours after surgery. And also need renal replacement therapy (RRT). Secondary outcomes included the hemodynamic variables, Blood products transfusion Results: There were signicant differences in BUN between groups at 4 h (P= 0.02) and 48h after surgery (P=0.001) There were signicant differences in Cr level between groups at 4 h (P <0.001) and 48h after surgery (P=0.001). MAP at different times (at 4h p=0.002 and 48h after surgery P<0.001) were signicantly different between the two groups. There was a signicant difference between the two groups in terms of the unit of Packed cell transfusion (P=0.002) and FFP transfusion (P<0.001). Conclusion: In the present study, we found that administration of N-acetyl cysteine can reduce the incidence of acute kidney injury in patients undergoing coronary artery bypass graft surgery and improved kidney functions. Trial registry:


Introduction
Open heart surgery for coronary artery bypass graft (CABG) is one of the major surgeries in adults (1).
Kidney failure is one of the most common complications of coronary artery bypass graft surgery. Even a very low increase in serum creatinine levels in these patients has been associated with an increase in mortality (2). Acute renal failure after coronary artery bypass graft (CABG) increases mortality, morbidity and the length of hospitalization in intensive care unit and some cases causes dialysis (2,3).
The main factors leading to acute renal failure after CABG are pre-operation renal dysfunction, heart failure, Diabetes Mellitus, and duration of CPB time, which may be considered as independent factors.
The age, CPB time, cross-clamp time, type of operation, poisons, metabolic factor, ischemia and reperfusion injury, activation of neurohormonal factors, in ammation, and oxidative stress responses are other risk factors., which increases the risk of post-CABG acute renal failure (4).
The frequency of acute renal failure necessitating renal replacement therapy (RRT) subsequent CPB is assessed to occur in up to 3.7% of patients, whereas azotemia, not requiring RRT, occurs in about 11.4% of patients (5).
Early diagnosis of Acute Kidney Injury (AKI) is very important for effective prevention and treatment.
Effective AKI treatment is depending on early monitoring of biomarkers. Serum creatinine levels are currently used to diagnose renal failure. However, this is not a reliable index during acute changes in kidney function (6), because its rate can be in the normal range even in patients with kidney damage greater than 50% (6). Renal failure is poor kidney function, which may be due to decreased blood ow to the kidneys caused by kidney artery disease. In general, the kidneys regulate uid and electrolytes and blood pressure, however, proper kidney function may be impaired in a condition called renal artery stenosis, in which the feeding arteries of the kidneys are narrowed, restricted, and weakened (7).
There are several measures, including maintaining su cient intravascular volume, adequate perfusion, and avoiding nephrotoxic drugs to prevent AKI. Some drugs such as Calcium Channel Blockers and Statins are also used to prevent the incidence of AKI (8).To achieve this goal, many researchers examined antioxidant molecules, including N-acetyl cysteine.
N-acetyl cysteine is an antioxidant derived from the amino acid cysteine is one of the medicines used to attenuate ischemic renal failure through nitric oxide-independent arteriolar vasodilation while functioning as an antioxidant and it can be preventing nephropathy caused by contrast agents are among the indications (9). It only shows antioxidant and anti-in ammatory effects at high doses. It seems the application of N-acetyl cysteine supplementation increases Glutathione, which is the main antioxidant in the body. Also, it reduces the formation of in ammatory cytokines such as interleukin-8 and tumor necrosis factor-alpha (9) Since no effective prevention methods have been found to inhibit acute renal failure after CABG surgery, this study is aimed to investigate the effect of N-acetyl cysteine injection on renal function after coronary artery bypass graft surgery.

Material And Method
Study design: This double-blind randomized clinical trial study was conducted in Golestan Hospital, Ahvaz, Iran, from Agust 2020 to January 2021 with Ethics code: IR.AJUMS.REC.1398.392 from Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, and Trial registration number: IRCT20190506043492N3(06/07/2020). Sixty patients undergoing elective on-pump coronary artery bypass graft surgery were included. After clearly explaining the objective and potential risks and bene ts of the study, a written consent form for participation in the study was obtained from all patients.

Setting and patients:
Inclusion criteria: Candidates for elective open CABG, aged 30 to 70 years.
Exclusion criteria included: The patient is not satis ed to participate in the study, renal and dysfunction based on KDIGO criteria(10), history of steroids and anti-in ammatory taking, acute myocardial infarction within fewer than 1 weeks, redo surgery, ejection fraction less than 30%, and complex surgeries.
Randomization and Blindness: The patients were randomized 1:1 to receive either (N-acetyl cysteine) or normal saline as control. To ensure that both the patients and the investigators were blind to the treatment group before the study begins, we used a computer-generated allocation-concealment process before recruiting the patients. The patients, surgeon, and investigator were unaware of the type of injectable drug and the surgeries performed by the same surgeon (The injectable drug was prepared by the researcher and named 1 and 2).
Sample size: The sample size of this study was calculated using the sample size estimation formula. The 95% con dence interval (CI) level was considered. The study population consisted of 60 patients. Based on the previous data (11).
After entrance to the operating room, standard monitoring included ve-lead electrocardiography, pulse oximetry, and arterial line for continuous blood pressure monitoring, and blood gases were inserted. The anesthesia technique, the surgeon, and the cardiopulmonary bypass procedure was intended to be as similar as possible. The patients after surgery were admitted to the cardiovascular ICU. Protocol for sedation (Dexmedetomidine 0/1-1 μg /kg/min), and management of mechanical ventilation (SIMV mode of ventilation) were similar for all patients and if they matched the weaning criteria, were extubated.

Intervention:
In the intervention group, after induction of anesthesia and intubation, and hemodynamic stabilization, 100 mg/kg N-acetyl cysteine that diluted in 100 ccs normal saline will be administered intravenously in 20 min, 100mg/kg in the Next 4 hours and100 mg/kg in the 16 hours after on. In the control group, normal saline will be administered in the same volume and at the same times.
Primary outcomes were serum levels of BUN and Cr, at baseline,4 and 48 hours after surgery. And also the need for renal replacement therapy (RRT).
Secondary outcomes: Included the hemodynamic variables, the number of unit of postoperative Paced cell and FFP transfusion (Paced cell transfusion was performed if the hemoglobin was less than 7mg/dl and FFP transfusion were performed if oozing was present and one FFP unit per blood unit ), Urine output.

Statistical analysis:
All statistical analysis was completed using SPSS version 22. Descriptive statistics are reported as mean ± standard deviation for continuous variables and as frequency and percentage for categorical variables. Parameters with a normal distribution were compared using the unpaired t-test, Statistical signi cance was de ned as a p-value < 0.05.

Results
During the study period from August 2020 to January 2021, 110 patients undergoing elective CABG surgery were quali ed to contribute to the trial. 80 patients agreed to contribute and written informed consent. Among them, 10 patients did not have inclusion criteria, 5 patients had a history of renal disease, and 5 patients were given steroid drugs. Finally, 60 patients were registered in the study and were allocated into two groups of N-acetyl cysteine and control (normal saline), 30 patients each (Consort diagram Fig. 1).
There were no signi cant differences between the two groups in terms of demographic characteristics (P > 0.05). Although serum Cr level was in the normal range in both groups, it was signi cantly lower in the NAC group than in the Control group at 4 hours (1.233 ± 0.307versus 1.337 ± 0.298 P < 0.001) and 48h after surgery (1.08 ± 0.279versus 1.17 ± 0.273 P = 0.001). Table 2  There was no signi cant difference between the two groups in terms of HR (p > 0/05). MAP at different times (at 4 hours p = 0.002 and 48h after surgery P < 0.001) were signi cantly different between the two groups. Table 3  Based on the results, the amount of urine Out Put was more in the intervention group than control at all times, but there was not signi cantly( P > 0.05). Table 3 Discussion The main purpose of this study was to investigate the effect of N-acetyl cysteine on renal function in patients undergoing elective coronary artery bypass graft surgery According to the results of the study, patients of the group receiving N-acetyl cysteine had a greater decrease in the level of Creatinine and BUN, indicating the positive effect of this drug on renal function.
In recent years, research on N-acetyl cysteine has been on the rise due to its protective effects on organ injuries caused by oxidative stress, especially kidney function (12). However, there are some contradictory reports about the protective effects of N-acetyl cysteine on the kidneys. Fisher et al. have shown that Nacetyl cysteine has bene cial effects on kidney function after heart surgery, which is consistent with the results of this study (13). However, in a study conducted by Burns on patients undergoing CABG, and in a study by Song et al they were found that there was no difference between patients of the N-acetyl cysteine and placebo groups in the risk of kidney function impairment (14,15). This may be due to some differences such as drug dosage or duration of follow-up.
Oxidative stress can be caused after reperfusion in cardiopulmonary bypass (CPB) (16). Renal dysfunction, especially in high-risk patients, is a common problem after cardiac surgery. To control this risk factor, in addition to routine treatments, it requires a more effective medication with fewer adverse effects. Researchers have studied many antioxidant molecules and have shown that it is only some molecules (such as N-acetyl cysteine and superoxide dismutase) that can show a positive impact on renal function and even improve it (17,18).
N-acetyl cysteine is the acetyl form of L-cysteine, which is converted into metabolites in the body that can synthesize glutathione, promote detoxi cation, and also has a direct effect on removing free radicals. It is used in various therapeutic cases such as acetaminophen poisoning, bronchitis, drug addiction, and schizophrenia. This compound is a derivative of cysteine in which an acetyl group is attached to the amino group in cysteine. NAC is essentially a precursor which is converted into cysteine (in the intestine by aminoacylase-1) and is absorbed into the bloodstream (19). Cysteine is a key component of glutathione and therefore, administration of NAC lls glutathione reserve. NAC can also be used as a general antioxidant that helps to reduce symptoms of many diseases that have been worsened by reactive oxygen species (ROS). Researches show that the use of N-acetyl cysteine can prevent acute renal failure in patients with renal failure (20).
In Mainra et al. study (2007), the effect of NAC administration on renal function in patients with chronic kidney disease was evaluated. In the study, 600mg NAC was orally prescribed for 30 patients and serum levels of Creatinine were measured at 4, 24, and 48 hours. Based on the results of this study, by our ndings, administration of NAC did not affect serum levels of Creatinine in these patients. Therefore, further studies with higher doses of drugs and long-term follow-up periods were suggested (21).
In the study of Rehman et al. (2008) in the same group of patients, administration of NAC did not affect serum levels of Creatinine (22).
The effect of NAC on renal function of patients with acute and chronic renal failure was investigated by Moist et al. (2010). NAC (1200mg) was administered at intervals of 12 hours. Finally, there was no signi cant effect on serum creatinine levels in the intervention group compared to the placebo group (23) The results of these studies were inconsistent with the ndings of our study.
Several studies have been conducted to evaluate the protective effects of N-acetyl cysteine on vital organs and tissues of the body in patients undergoing cardiac surgery. In a 2018 study, Amini et al. found that treatment with N-acetyl cysteine was effective in preventing kidney damage and its association with CABG-related deaths (24). This is partially similar to the present study.
Şavluk et al. in a study stated that intravenous administration of N-acetylcysteine is associated with improved kidney function tests in patients with renal failure (25). These ndings are partly by our ndings.
In 2016, Aldemir et al. achieved results consistent with our study during a clinical trial to investigate the effect of NAC on performance and post-CABG renal function tests. Plasma creatinine levels in the placebo group at 24 hours after surgery were signi cantly higher than the N-acetylcysteine group. In this study, they found that intravenous administration of NAC in elderly patients undergoing surgery prevents acute kidney damage and improves the results of renal function tests (26) In a meta-analysis study in patients undergoing angiography,  concluded that there is a signi cant difference in using N-acetyl cysteine in preventing nephropathy following coronary angiography, and further studies on the use of NAC among high-risk patients are necessary (27).In another study, Ozaidan et al. concluded in 2014 that the use of N-acetyl cysteine was effective in reducing the incidence of acute kidney damage following CABG (28). Both of these studies are in line with the results of the present study.
In a 2015 study, Wang et al. studied the effect of N-acetyl cysteine administration on acute kidney damage after coronary artery bypass graft surgery and concluded that serum creatinine levels were the same in both groups, but the urinary output was lower in the control group than in the NAC group. They stated that NAC administration does not prevent the progression of acute kidney damage after surgery and further studies are needed (29)Although this study is consistent with our study in urinary output indicator, the effect of N-acetyl cysteine on serum creatinine levels is different. The reason for this difference can be due to the variance in the sample size of the two studies.
The results of the present study showed that N-acetyl cysteine signi cantly improves renal function tests and can be effective in reducing ischemic renal damage. This effect of N-acetyl cysteine can be considered as a result of the effects of this drug on the glutathione system or due to the antiin ammatory and antioxidant effects of N-acetyl cysteine.

Limitations
This study has several limitations. First; the sample size was small second; this study was singlecentered. Another limitation of this study was the lack of complications in patients.
We recommended future trials with large sample size, multi-center, and long duration of follow-up.

Conclusion
In conclusion, the administration of NAC can be reduced BUN and Creatinine levels and the incidence of kidney injury in patients undergoing CABG and mitigates the negative effect of CPB on kidney function. Abbreviations CABG: coronary artery bypass graft; CPB: Cardio pulmonary bypass; AKI: Acute kidney injury; KDIGO: Kidney Disease Improving Global Outcomes; ICU: Intensive care unit; RRT: Renal replacement therapy Declarations Competing interests: There is no con ict of interest to be declared.
Funding: Financial support for this study was provided by Ahvaz Jundishapur University of Medical Sciences.
Ethics approval and Consent to participate: This paper was part of a thesis Ethics code: (IR.AJUMS.REC.1398.392 was received from Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. The RCT code of this study was IRCT20190506043492N3. Written informed consent signed by all patients Consent for publication: Authors provide formal written consent to publish before publication Availability of data and material: All data were retrieved from the institutional database and are available from the corresponding authors upon reasonable request. Figure 1 CONSORT Flow Diagram: Eighty subjects were enrolled in the study, of which 60 met the criteria for the study and consented to participate. Participants were divided into two groups (each with 30 subjects).